TriNessa

Low vitamin B6 status can promote accumulation of homocysteine, a sulfur‑containing amino acid that can damage the endothelium, increase oxidative stress, and promote clot formation, all of which are relevant to cardiovascular disease and stroke. Large observational studies and cross‑sectional analyses have shown that people with lower plasma pyridoxal‑5‑phosphate (active B6) levels have higher rates of stroke and other vascular events, and in some cohorts low B6 was a stronger predictor of stroke or transient ischemic attack than homocysteine itself. The encouraging finding from meta‑analyses and clinical trials is that B‑vitamin combinations including B6 can lower homocysteine and modestly reduce the combined risk of stroke, myocardial infarction, and vascular death in high‑risk patients, suggesting that maintaining adequate B6 is one useful piece of broader cardiovascular prevention

In the brain, vitamin B6 (pyridoxine) is needed to produce neurotransmitters and to keep homocysteine in check, so low B6 status has been linked to both depressed mood and subtle cognitive problems such as slower processing and poorer attention in some adults. Observational work in older populations suggests that lower blood levels or intakes of B6 tend to track with worse performance on memory, executive‑function, and psychomotor‑speed tests, raising concern that marginal B6 status may contribute to age‑related cognitive decline. Clinically, when B6 deficiency coexists with depression, correcting it is viewed as one modifiable factor that may help support clearer thinking and better cognitive function alongside standard psychiatric and lifestyle treatments.

Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.

Low or depleted magnesium levels are associated with a higher likelihood of several cardiovascular problems, including arrhythmias, where people with low magnesium have been shown to have 2–4 times higher odds of these rhythm disturbances compared with those with normal levels. Low magnesium is also linked to worsening coronary artery disease, progression of heart failure, and development or aggravation of hypertension, driven by disrupted cardiac electrical stability, vascular function, and electrolyte balance. Even mild magnesium depletion may contribute to higher blood pressure over time, adding to the overall cardiovascular burden, especially in individuals with existing heart disease or multiple risk factors.

In susceptible adults, acute thiamine (vitamin B1) deficiency can rapidly trigger an encephalopathy marked by confusion, gait ataxia, and ocular motor abnormalities such as nystagmus or ophthalmoplegia. This classic triad is often incomplete at presentation, and only a minority of patients show all three features together initially, which contributes to delayed diagnosis. Because body stores are quickly exhausted, maintaining adequate ongoing thiamine intake is critical, and can reverse many of the acute neurologic signs if started early, whereas even short delays increase the risk of persistent cognitive impairment and structural brain injury on imaging.

Low zinc status has been linked to a higher risk and faster progression of age-related macular degeneration (AMD), in part because zinc is concentrated in the retina and supports antioxidant defenses there. In the landmark AREDS trial, a supplement formula containing zinc (80 mg as zinc oxide), along with antioxidants, reduced the risk of progression to advanced AMD by about 25% in people with intermediate disease or advanced disease in one eye over roughly 5 years. Other research has shown that inadequate zinc intake is more common in older adults with AMD, reinforcing the idea that maintaining healthy zinc levels may be an important, and often overlooked, strategy for preserving macular health with age.